PARN: A Potential Drug Target and Biomarker (G5073)

Target Name: PARN

NCBI ID: G5073

PARN: A Potential Drug Target and Biomarker

Parbinuclease (PARN) is a 2',3'-exoribonuclease enzyme that is found in various organisms, including bacteria, archaea, and eukaryotes. It is involved in the DNA damage response pathway, which is a critical process that helps cells respond to DNA damage caused by various factors, such as UV radiation, radiation, and chemicals. PARN plays a crucial role in the regulation of DNA double-strand breaks, which are critical for the stability and integrity of chromosomes.

The discovery of PARN as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. PARN has been shown to be involved in the development of DNA damage, which can lead to the development of cancer. Therefore, targeting PARN may be an effective way to prevent the development of cancer.

One of the key advantages of targeting PARN is its specificity to DNA damage. Unlike many other proteins that can be targeted by drugs, PARN is specific to DNA damage and has been shown to play a critical role in the regulation of the DNA double-strand break response. This means that targeting PARN will not have unintended effects on other proteins and is expected to be more effective and less toxic than other treatments.

Another advantage of targeting PARN is its potential to treat a wide range of diseases. DNA damage is a common occurrence in many diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, targeting PARN may be an effective way to treat a wide range of diseases that are currently untreated or have limited treatment options.

The development of PARN as a drug target and biomarker is still in its early stages, but it has the potential to be a valuable tool for the development of new treatments for various diseases. Further research is needed to fully understand the role of PARN in the regulation of DNA damage and to identify potential drug targets.

In conclusion, PARN is a promising drug target and biomarker with significant potential for the development of new treatments for various diseases. Further research is needed to fully understand its role in the regulation of DNA damage and to identify potential drug targets. If successful, targeting PARN may be an effective way to prevent the development of cancer and treat a wide range of diseases.

Protein Name: Poly(A)-specific Ribonuclease

Functions: 3'-exoribonuclease that has a preference for poly(A) tails of mRNAs, thereby efficiently degrading poly(A) tails. Exonucleolytic degradation of the poly(A) tail is often the first step in the decay of eukaryotic mRNAs and is also used to silence certain maternal mRNAs translationally during oocyte maturation and early embryonic development. Interacts with both the 3'-end poly(A) tail and the 5'-end cap structure during degradation, the interaction with the cap structure being required for an efficient degradation of poly(A) tails. Involved in nonsense-mediated mRNA decay, a critical process of selective degradation of mRNAs that contain premature stop codons. Also involved in degradation of inherently unstable mRNAs that contain AU-rich elements (AREs) in their 3'-UTR, possibly via its interaction with KHSRP. Probably mediates the removal of poly(A) tails of AREs mRNAs, which constitutes the first step of destabilization (PubMed:10882133, PubMed:11359775, PubMed:12748283, PubMed:15175153, PubMed:9736620). Also able to recognize and trim poly(A) tails of microRNAs such as MIR21 and H/ACA box snoRNAs (small nucleolar RNAs) leading to microRNAs degradation or snoRNA increased stability (PubMed:25049417, PubMed:22442037)

More Common Targets